AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain. The company’s leading product candidate, Zalviso™, is designed for the management of moderate-to-severe acute pain in adults in the hospital setting by utilizing a high therapeutic index opioid through a non-invasive delivery route via a pre-programmed, patient-controlled analgesia device. In early September, the company plans to meet with the FDA regarding the submittal of a new drug application for Zalviso. For more information, visit the company’s website at www.acelrx.com.